Consolidated results for the first quarter of the fiscal year ending December 2026
Carna Biosciences,Inc. (reporting company) and the consolidated group
Drug discovery business (docirbrutinib (AS-1763), sofnobrutinib (AS-0871), and monzosertib (AS-0141)) and drug discovery support business. Clinical trials for docirbrutinib are underway in the United States, and those for monzosertib are underway in Japan.
Substantial upfront investment is required, primarily for clinical trial-related expenses for the BTK inhibitor docirbrutinib and the CDC7 inhibitor monzosertib, and cash on hand at the end of the period may be insufficient to fund future research and development activities.
Revenue of ¥183 million, operating loss of ¥458 million, ordinary loss of ¥488 million, and quarterly net loss attributable to owners of the parent of ¥513 million. The Company recorded an extraordinary loss of ¥23 million, comprising an impairment loss of ¥3 million and a loss on redemption of bonds of ¥20 million.
First quarter of the fiscal year ending December 2026 (1 January 2026 to 31 March 2026)
There is no change to the consolidated earnings forecasts for the fiscal year ending December 2026.
Company response
New patient enrollment in the Phase 1 trial of GS-9911 at Gilead (August 2025)
(1) Advance clinical trials for the development-stage pipeline and obtain upfront licensing payments and milestone income by entering into license agreements; (2) secure funding through operating cash flow from the drug discovery support business; and (3) conduct new fundraising. Carna Biosciences,Inc. aims to enter into an agreement for docirbrutinib in 2026 and is preparing to execute a Clinical Trial Agreement (CTA) and commence a trial for monzosertib.
New interim results for docirbrutinib are scheduled to be presented at the European Hematology Association Congress (EHA2026) in June 2026.
| Item | Details |
|---|---|
| Event name | Consolidated results for the first quarter of the fiscal year ending December 2026 |
| Date of occurrence | 31 March 2026 (end of the first quarter of the fiscal year ending December 2026) |
| Subject Entity | Carna Biosciences,Inc. (reporting company) and the consolidated group |
| Target Locations / Products | Drug discovery business (docirbrutinib (AS-1763), sofnobrutinib (AS-0871), and monzosertib (AS-0141)) and drug discovery support business. Clinical trials for docirbrutinib are underway in the United States, and those for monzosertib are underway in Japan. |
| Cause | Substantial upfront investment is required, primarily for clinical trial-related expenses for the BTK inhibitor docirbrutinib and the CDC7 inhibitor monzosertib, and cash on hand at the end of the period may be insufficient to fund future research and development activities. |
| Amount of Impact on Business Performance | Revenue of ¥183 million, operating loss of ¥458 million, ordinary loss of ¥488 million, and quarterly net loss attributable to owners of the parent of ¥513 million. The Company recorded an extraordinary loss of ¥23 million, comprising an impairment loss of ¥3 million and a loss on redemption of bonds of ¥20 million. |
| Accounting period in which recognized | First quarter of the fiscal year ending December 2026 (1 January 2026 to 31 March 2026) |
| Impact on Earnings Forecast | There is no change to the consolidated earnings forecasts for the fiscal year ending December 2026. |
| Suspended operations | New patient enrollment in the Phase 1 trial of GS-9911 at Gilead (August 2025) |
| Outlook | (1) Advance clinical trials for the development-stage pipeline and obtain upfront licensing payments and milestone income by entering into license agreements; (2) secure funding through operating cash flow from the drug discovery support business; and (3) conduct new fundraising. Carna Biosciences,Inc. aims to enter into an agreement for docirbrutinib in 2026 and is preparing to execute a Clinical Trial Agreement (CTA) and commence a trial for monzosertib. |
| Planned follow-up disclosure | New interim results for docirbrutinib are scheduled to be presented at the European Hematology Association Congress (EHA2026) in June 2026. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company continues to incur operating losses because it is making substantial upfront investments, primarily in clinical trial-related expenses. It also recorded interest expenses, costs of issuing stock acquisition rights, foreign exchange losses, and losses on redemption of bonds. The Company states that a material uncertainty exists regarding the going concern assumption because cash on hand at the end of the period may be insufficient to fund the research and development activities required in the future.